Merrimack's Prospects Dim As MM-141 Fails Pancreatic Cancer Phase II Trial

Merrimack Pharmaceuticals has ended development of its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.